Four studies showed Prolacta Bioscience’s 100% human milk-based fortifiers reduced retinopathy of prematurity (ROP) in premature infants
Type: Press Releases
Topic(s): Retinopathy of Prematurity (ROP)
Prolacta Bioscience provides update on latest SARS-CoV-2 data and continued safety of its human milk-based nutritional products
Type: Press Releases
Topic(s): Quality & Safety
Late-onset sepsis reduced in premature infants fed Prolacta’s 100% human milk-based fortifiers as part of an exclusive human milk diet
Type: Press Releases
Topic(s): Clinical Studies Clinical Studies on Prolact/Humavant CR Late-Onset Sepsis
Prolacta Bioscience fortifiers reduce risk of serious lung disease and hospital costs among premature infants, compared to cow milk-based fortifiers
Type: Press Releases
Topic(s): Bronchopulmonary Dysplasia (BPD)
NICU parents help other new parents through difficult times
Type: Parent Stories Press Releases
Topic(s): Parents
Research suggests some premature infants may go home from the NICU Up to 3 weeks earlier when fed Prolacta’s 100% human milk-based nutritional products; those with bronchopulmonary dysplasia may benefit the most
Type: Press Releases
Topic(s): Bronchopulmonary Dysplasia (BPD) Length of hospital stay
Multiple NICUs showed improved growth & lung health in premature infants by fortifying feeds safely in the first days of life with Prolacta’s 100% human milk-based fortifiers
Type: Press Releases
Topic(s): Bronchopulmonary Dysplasia (BPD) Early Fortification Feeding Protocols Growth Necrotizing Entercolitis (NEC) Product
The preemie parent’s survival guide to the NICU now reflects the latest clinical advancements to better support parents worldwide
Type: Press Releases
Topic(s): Company Growth Parents
Preterm infants fed Prolacta’s 100% human milk-based fortifiers achieved catch-up growth by age 2 with appropriate neurodevelopmental outcomes, study says
Type: Press Releases
Topic(s): Growth Long-Term outcomes
